(Q24240282)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

title

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Toby J Lasserson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

7 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

CD007695

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19821436%20AND%20SRC:MED&resulttype=core&format=json

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Long-term studies on long-acting sympathomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Beta-adrenergic receptors and their regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Systemic effects of salbutamol and salmeterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Lack of Evidence for Beta-2 Receptor Selectivity: a Study of Metaproterenol, Fenoterol, Isoproterenol, and Epinephrine in Patients with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

The cardio-toxicity of isoprenaline during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Beyond the dogma: novel beta2-adrenoceptor signalling in the airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Recovery from bronchoconstriction and bronchodilator tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Further observations on the cardiotoxicity of isoprenaline during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Observations on recent increase in mortality from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Beta-adrenoceptors and the epithelial layer in airways

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Regular inhaled salbutamol and airway responsiveness to allergen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

A comparison of salmeterol and formoterol in attenuating airway responses to short-acting β2-agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Tolerance to beta-agonists during acute bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Hypokalemia from Beta2-Receptor Stimulation by Circulating Epinephrine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Potential masking effects of salmeterol on airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Beta-agonist intrinsic efficacy: measurement and clinical significance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021

Comparison of the Bronchodilator Effect of Inhaled Short- and Long-Acting beta(2)-Agonists in Children with Bronchial Asthma: A Randomised Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007695.PUB2

7 January 2021